

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except common share information)

	Year Ended December 31,	
	2024	2023
Revenue from government contract	\$ 3,955	\$ -
Operating expenses:		
Research and development	23,714	20,721
General and administrative	5,385	6,022
	29,099	26,743
Loss from operations	(25,144)	(26,743)
Other income (expense), net	152	776
Net loss	\$ (24,992)	\$ (25,967)
Net loss per common share	\$ (4.82)	\$ (14.29)
Weighted averages shares outstanding	5,187,038	1,817,282

Condensed Consolidated Balance Sheet Information
(amounts in thousands, except common share information)

	December 31,	
	2024	2023
Assets		
Cash and cash equivalents	\$ 5,507	\$ 6,453
Other current assets	2,428	1,433
Total current assets	7,935	7,886
Property and other assets	221	1,397
Total assets	\$ 8,156	\$ 9,283
Liabilities and stockholders' equity		
Total liabilities	\$ 3,107	\$ 3,520
Stockholders' equity	5,049	5,763
Total liabilities and stockholders' equity	\$ 8,156	\$ 9,283
Common shares outstanding	10,536,875	1,977,152